The Eighth Annual International Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Eighth Annual International Employment Survey


Pharmaceutical Technology


Survey participants were asked to describe what they enjoy best and least about their jobs. Perhaps not surprising, issues related to job environment topped the list of greatest annoyances. Workers expressed frustration over company politics and office culture, a lack of support from management, too much paperwork, and pressures of having to do more with fewer resources. Intellectual challenge, problem solving, a sense of purpose in the objective of their jobs (developing effective therapeutic products), and good coworkers were often cited as the best satisfactions of the job. To some degree, responses depended on the type of work. For example, one independent consultant in the UK valued independence and flexibility saying "My job environment is as I wish it to be. Being independent gives me total control in this regard." Nonetheless, he also listed "stability, income, governmental inertia or interference, and regulatory policies" as major concerns in his field.

Preferred employer. A job change in the next 12 months seems to be on the minds of more people this year. Although most (57%) workers said it was unlikely or very unlikely that they will change employment within the next year, this value is lower than the 61% result from last year's survey. About one-third said the possibility of a job change was likely or very likely. Even if a job change were made, nearly 70% of respondents would prefer to work in private industry over any other sector, including nonprofit agencies, academic institutions, or government.


Table V: Importance of various skills in performing daily tasks.
Essential skills and knowledge. Participants weighed in on the importance of various skills (see Table V). Managers often emphasize these skills regardless of the type of job function. For example, in a follow-up conversation, Hayes Powell, a principal scientist who oversees a staff of laboratory scientists at AMO, a company that has undergone several changes since parting with parent company Allergan, said "Restructuring often opens up other opportunities, and companies tend to rehire [personnel] to fill these positions during restructuring." Powell, who has worked in the industry for 32 years, also says he has seen improvement over the past 10–15 years in the skill set of newly hired personnel, especially in written communication and entry-level preparedness.


Table VI: Influence of regulatory guidelines.
Impact of regulations and legislations. For the first time, our questionnaire asked employees to indicate their awareness of various regulatory initiatives and gauge the effect of these initiatives on the manner in which they perform their jobs. The Food and Drug Administration's rule on electronic records and signatures (21 CFR Part 11) has made the biggest impact so far. Only 6% said they are not aware of the rule (see Table VI).

In a follow-up discussion, one (anonymous) pharma manufacturing manager pointed out that many companies are certainly aware of these initiatives, especially FDA's process analytical technologies guidelines, but are choosing to monitor the experiences of Big Pharma before beginning major changes.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
36%
Facility/environment problems
0%
Process development problems
9%
Production equipment downtime
9%
Raw material supply problems
27%
Regulatory restrictions
0%
Business decisions to limit production
18%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here